

Anexo2. Tabla de resultados: SEGURIDAD

Tipo de evento adverso	Estudio
Eventos adversos leves que no condicionan retirada	Bharadwaj 2007 [41]
Retirada/Suspensión/Ineficacia	Arthur 1999 [14]; Branco 2016 [18]; Bingham 2003 [42]; Calasan 2013 [43]; Demary 2014 [22]; Dhaon 2017 [44]; Gridneva 2018 [45]; Hazlewood 2016 [46]; Müller-Ladner 2010 [19]; Rau 1997 [47]; Sampaio-Barros 2000 [48]; Scott 2014 [49]; Thompson 1984 [50]; Thornton 2008 [51]
Eventos adversos no especificados	Branco 2016 [18]; Borman 2014 [52]; Burbage 2001 [11]; Hazlewood 2016 [46]; Müller 2015 [53]
Eventos adversos gastrointestinales (náuseas, vómitos, diarrea, dispepsia, dolor abdominal, pérdida de apetito)	Arthur 1999 [14]; Bingham 2003 [42]; Braun 2008 [7]; Calasan 2013 [43]; Curtis 2016 [54]; Demary 2014 [22]; Dhaon 2013 [55]; Dhaon 2017 [44]; Gridneva 2015 [56]; Haibel 2007 [57]; Huber 2006 [58]; Islam 2013 [8]; Lafforgue 1995 [29]; Lambert 2004 [59]; Michaels 1982 [60]; Myasoutova 2016 [61]; O'Connor 2016 [62]; Przygodzka 2017 [63]; Rau 1997 [47]; Rutkowska-Sak 2009 [64]; Sampaio-Barros 2000 [48]; Thompson 1984 [50]
Eventos adversos mucocutáneos (problemas bucales, rash pruriginoso; nodulosis; pérdida de cabello; úlceras orales)	Arthur 1999 [14]; Bingham 2003 [42]; Burbage 2001 [11]; Curtis 2016 [54]; Dhaon 2017 [44]; Gridneva 2015 [56]; Gridneva 2018 [45]; Islam 2013 [8]; Lambert 2004 [59]; Michaels 1982 [60]; Myasoutova 2016 [61]; Rau 1997 [47]; Sampaio-Barros 2000 [48]
Elevación de transaminasas	Bianchi 2018 [65]; Braun 2008 [7]; Dhaon 2017 [44]; Gridneva 2015 [56]; Gridneva 2018 [45]; Harris 2018 [66]; Huber_ 2006 [58]; Lafforgue 1995 [29]; Lambert 2004 [59]; Müller-Ladner 2010 [19]; Myasoutova 2016 [61]; Rau 1997 [47]; Sampaio-Barros 2000 [48]; Thompson 1984 [50]
Eventos adversos pulmonares (pneumonitis intersticial, bronquitis)	Arthur 1999 [14]; Braun 2008 [7]; Dhaon 2017 [44]
Eventos adversos neurológicos (cefalea)	Braun 2008 [7]; Dhaon 2017 [44]; Freundlich 2014 [23]; Islam 2013 [8]; Lambert 2004 [59]; O'Connor 2016 [62]
Eventos adversos hematológicos	Dhaon 2017 [44]; Gridneva 2015 [56]; Finckh 2014 [13]; Lafforgue 1995 [29]; Lambert 2004 [59]; Müller – Ladner 2010 [19]; Sames 2014 [67]; Stamp 2011 [16]; Thompson 1984 [50]
Eventos adversos cardíacos (enfermedad del seno, infarto agudo de miocardio, eventos cardiovasculares)	Schiff 2014_2 [24]; Schiff 2017 [68]; Todoerti 2016 [69]
Eventos adversos generales (fatiga, malestar general, confusión, astenia, mareo, febrícula, síndrome gripal)	Bianchi 2018 [65]; Chichasova 2018 [70]; Curtis 2016 [54]; Islam 2013 [8]; Lafforgue 1995 [29]; Lambert 2004 [59]; Schiff 2014_2 [24]
Eventos adversos infecciosos	Curtis 2016 [54]; Demary 2014 [22]; Dhaon 2017 [44]; Haibel 2007 [57]; Lambert 2004 [59]
Eventos adversos locales (en relación con el sitio de inyección, problemas con el dispositivo)	Curtis 2016 [54]; Demary 2014 [22]; Gridneva 2015 [56]; Gridneva 2018 [45]; Huber_ 2006 [58]; Müller-Ladner 2010 [19]; Myasoutova 2016 [61]; Saraux 2019 [71]; Schiff 2014_2 [24]